HAIFA, Israel, April 3, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that it has formed a steering committee to assist in advancing PLacental eXpanded (PLX) cell therapies for the treatment of Peripheral Artery Disease (PAD). The committee is comprised of vascular and immunological specialists from around the world who will offer expertise to Pluristem in furthering cell treatments for Critical Limb Ischemia (CLI), Intermittent Claudication (IC) and Buerger’s Disease.
